Structure Therapeutics Inc. Share Price & Technical Analysis
GPCR · $39.19 (+1.03%)
Healthcare / Biotechnology
$39.19
+1.03%
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment …
Price chart
Seasonality
May has 1 positive and 3 negative years (last 4 years shown)
-11% return in May, -3% avg return in past 3 year May month.
-50% return in 2026, 72% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 27% | -28% | -22% | -16% | -11% | – | – | – | – | – | – | – | -50% |
| 25 | 10% | -17% | -27% | 59% | -20% | -6% | -14% | 10% | 46% | 19% | 8% | 97% | 165% |
| 24 | 10% | -8% | 6% | -9% | -13% | 11% | -6% | 2% | 17% | -6% | -19% | -18% | -33% |
| 23 | – | 2% | -12% | 9% | 25% | 27% | -12% | -23% | 77% | 46% | -26% | -30% | 84% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.67B
P/E ratio
—
52W high
$94.90
52W low
$15.80
Volume
7,32,992
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Structure Therapeutics Inc. share price today?
- Structure Therapeutics Inc. (GPCR) last traded around $39.19 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GPCR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GPCR. Download the app for real-time alerts.
- How can I analyze Structure Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.